Physician profile
Daniel Q Le
NPI 1902828569
$4,299.66
in general payments reported to CMS, 2019-2025
25 companies · $214 in 2025
The $214 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,539 · 2020: $468 · 2021: $303 · 2022: $477 · 2023: $180 · 2024: $118 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $511.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $1,948.21 | 2019 | |
| Micromed INC | $357.03 | 2019 | |
| Abbott Laboratories | $339.22 | 2021-2022 | |
| Forte Bio-Pharma LLC | $249.87 | 2020-2023 | Prolate, Nalocet |
| Pacira Therapeutics, INC. | $223.48 | 2020-2021 | |
| Abbvie INC. | $177.50 | 2022-2023 | |
| Globus Medical, INC. | $153.03 | 2025 | Senza |
| Stimwave Technologies Incorporated | $144.69 | 2020 | |
| Bioventus LLC | $112.77 | 2020-2021 | |
| Nalu Medical, INC. | $98.15 | 2020 | |
| Nevro Corp. | $96.62 | 2019-2024 | Senza |
| Saluda Medical Americas, INC. | $92.97 | 2024 | Evoke |
| Ibsa Pharma INC. | $45.08 | 2025 | Licart, Flector, Tirosint |
| Shionogi INC | $42.78 | 2019 | |
| Collegium Pharmaceutical, INC. | $38.64 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Painteq LLC | $26.68 | 2023 | Painteq |
| Janssen Pharmaceuticals, INC | $25.55 | 2019 | |
| Si-Bone, INC. | $24.66 | 2019 | |
| Mannkind Corporation | $19.59 | 2019 | |
| Radius Health, INC. | $18.27 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $15.94 | 2025 | Zilretta, Iovera |
| Pfizer INC. | $13.91 | 2019 | |
| Amphastar Pharmaceuticals, INC. | $13.60 | 2023 | Baqsimi |
| Biodelivery Sciences International, INC. | $12.41 | 2020 | |
| Spr Therapeutics, INC | $9.01 | 2024 | Sprint Pns System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.